CEA-PRIT 2.0 for Colorectal Cancer

This trial tests a new treatment called CEA-PRIT 2.0, a targeted therapy for individuals with colorectal cancer that has metastasized and not responded to standard treatments. The study aims to determine the safety, effectiveness, and behavior of this treatment in the body. Participants will receive varying doses to identify the most effective one. This trial may suit those with metastatic colorectal cancer, previous unsuccessful treatments, and a specific tumor type known as microsatellite-stable (MSS). As a Phase 1 trial, the research focuses on understanding the treatment's effects in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial protocol does not specify if you need to stop taking your current medications. However, you must not have had any anticancer treatment or investigational agent within 4 weeks before starting the trial.

Earlier studies found CEA-PRIT 2.0 to be safe. The treatment slowed tumor growth and caused only mild, temporary weight loss in participants. Importantly, it effectively targeted tumors while limiting effects on healthy tissues. These findings suggest that CEA-PRIT 2.0 is well-tolerated, with few reported side effects.¹²³⁴⁵

CEA-PRIT 2.0 is unique because it targets colorectal cancer with a novel approach involving radioimmunotherapy. Unlike standard treatments like chemotherapy and targeted therapies, CEA-PRIT 2.0 uses SeParated v-domains LInkage Technology Antibodies (SPLIT Abs) combined with 212Pb-DOTAM, a radioactive substance that delivers targeted radiation directly to cancer cells. This method not only aims to improve accuracy in attacking cancer cells but also minimizes damage to healthy tissue. Researchers are excited about its potential to enhance treatment effectiveness and reduce side effects compared to conventional therapies.

Research has shown that CEA-PRIT 2.0 could effectively treat colorectal cancer. In this trial, participants will receive CEA-PRIT 2.0, which combines antibodies and radioactive substances to target cancer cells, focusing treatment on tumors and minimizing harm to healthy tissue. Studies have found that this treatment can slow tumor growth with only mild side effects, such as temporary weight loss. Early results suggest this method strongly inhibits tumor growth and is safe. Tests in mice also showed positive outcomes, with the treatment effectively targeting tumors and causing limited side effects.¹³⁴⁵⁶